Oncology Institute Inc (TOI) concluded trading on Thursday at a closing price of $3.04, with 7.09 million shares of worth about $21.54 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 1069.23% during that period and on May 15, 2025 the price saw a gain of about 28.27%. Currently the company’s common shares owned by public are about 88.93M shares, out of which, 38.24M shares are available for trading.
Stock saw a price change of 4.11% in past 5 days and over the past one month there was a price change of 60.00%. Year-to-date (YTD), TOI shares are showing a performance of 883.82% which increased to 249.75% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $3.50 during that period. The average intraday trading volume for Oncology Institute Inc shares is 974.48K. The stock is currently trading 11.56% above its 20-day simple moving average (SMA20), while that difference is up 69.41% for SMA50 and it goes to 296.94% higher than SMA200.
Oncology Institute Inc (NASDAQ: TOI) currently have 88.93M outstanding shares and institutions hold larger chunk of about 11.99% of that.
The stock has a current market capitalization of $271.15M and its 3Y-monthly beta is at 0.03. It has posted earnings per share of -$0.70 in the same period. It has Quick Ratio of 1.59 while making debt-to-equity ratio of 20.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TOI, volatility over the week remained 16.52% while standing at 17.42% over the month.
Stock’s fiscal year EPS is expected to rise by 46.48% while it is estimated to increase by 76.32% in next year. EPS is likely to grow at an annualized rate of 58.70% for next 5-years, compared to annual growth of -488.57% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on May 15, 2025 offering a Buy rating for the stock and assigned a target price of $7 to it. Coverage by Jefferies stated Oncology Institute Inc (TOI) stock as a Buy in their note to investors on February 26, 2024, suggesting a price target of $2.50 for the stock. On September 14, 2022, Guggenheim Initiated their recommendations, while on August 15, 2022, Jefferies Initiated their ratings for the stock with a price target of $10.
